Last reviewed · How we verify
NCT05239923
COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores
NA trial testing Bacillus subtilis in COVID-19 Pneumonia in 35 participants. Completed in 30 December 2021.
30 November 2021
Quick facts
| Lead sponsor | DreamTec Research Limited |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 35 |
| Start date | 28 August 2021 |
| Primary completion | 30 November 2021 |
| Estimated completion | 30 December 2021 |
| Sites | 2 locations across Hong Kong, Iran |
Drugs / interventions tested
- Bacillus subtilis — full drug profile →
Conditions studied
- COVID-19 Pneumonia — all drugs for COVID-19 Pneumonia →
Sponsor
DreamTec Research Limited — full company profile →
Who can join
12 and older, any sex, with COVID-19 Pneumonia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a study trial to assess the effectiveness of the immune response stimulated by the genetically engineered Bacillus subtilis which express and display Spike protein of the SARS-COV2 on the spore coat.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Oral mucosa immunity: ultimate strategy to stop spreading of pandemic viruses.
Jang H, Matsuoka M, Freire M. · · 2023 · cited 6× · PMID 37928529 · DOI 10.3389/fimmu.2023.1220610 -
Blades and barriers: Oral vaccines for conquering cancers and warding off infectious diseases.
Yang K, Liu J, Zhao Y, Xu H, et al · · 2025 · PMID 40893667 · DOI 10.1016/j.apsb.2025.05.038
Verify or expand the search:
- PubMed search for NCT05239923
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Bacillus subtilis
Trials testing the same drug.
- NCT05057923 — The Development of a COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores · NA · completed
Other recruiting trials for COVID-19 Pneumonia
Currently open trials in the same condition.
- NCT06601998 — Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19. · recruiting
- NCT06501599 — AI-based System for Assessing Suspected Viral Pneumonia Related Lung Changes · recruiting
- NCT06402318 — Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine · recruiting
- NCT05765396 — SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies · active not recruiting
- NCT06927622 — Corona Virus Disease 2019 Cohort Study · recruiting
Other DreamTec Research Limited trials
Trials by the same sponsor.
- NCT05057923 — The Development of a COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores · NA · completed
- NCT05158855 — Oral Neutralizing Antibody Booster for Post-vaccinated People With COVID19 Vaccine · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05239923 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by DreamTec Research Limited
- Last refreshed: 15 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05239923.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing